Neonatal Alloimmune Thrombocytopenia
Conditions
Keywords
Neonatal Alloimmune Thrombocytopenia, pregnancy, human platelet allogantigen, asian, Chinese
Brief summary
This clinical study aims to investigate the anti-HPA antibodies caused neonatal alloimmune thrombocytopenia in Chinese pregnant women. The survey and data collect will help form an appropriate clinical screening procedure
Interventions
PROCEDUREStandard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion
Observational study.
Sponsors
Air Force Military Medical University, China
Shengjing Hospital
Qilu Hospital of Shandong University
Second Xiangya Hospital of Central South University
LanZhou University
The First Affiliated Hospital of Bengbu Medical University
The Affiliated Hospital Of Guizhou Medical University
Sir Run Run Shaw Hospital
Jilin University
First Affiliated Hospital of Xinjiang Medical University
People's Hospital of Xinjiang Uygur Autonomous Region
Second Affiliated Hospital of Nanchang University
Guangzhou First People's Hospital
The Affiliated Hospital Of Southwest Medical University
Beijing Chao Yang Hospital
Qingdao University
Peking University First Hospital
RenJi Hospital
First Affiliated Hospital of Harbin Medical University
MCH Hospital of Yinchuan City
Henan Provincial People's Hospital
Third Affiliated Hospital, Sun Yat-Sen University
The First Affiliated Hospital of Guangdong Pharmaceutical University
Xinqiao Hospital of Chongqing
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* 12-28 weeks pregnant Chinese women * between Jan 1, 2017 and Dec 31, 2018
Exclusion criteria
* Not willing to participate in this study * Plan to terminate pregnancy early
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The positive rate of anti-HPA antibody | Up to one and a half years after the study completed |
| The morbidity of NAIT | Up to one and a half years after the study completed |
Secondary
| Measure | Time frame |
|---|---|
| Antigenic specificity of anti-HPA antibodies | Up to one and a half years after the study completed |
| Association of anti-HPA antibody with HLA genotype as assessed by Chi-square test | Up to one and a half years after the study completed |
| The relationship between the titer of anti-HPA antibody and clinical symptom severity in NAIT as assessed by Spearman Correlation assay | Up to one and a half years after the study completed |
Contacts
Primary ContactLi Chen
Outcome results
None listed